A Multi-Institutional, Open-Label, Two-Group, Phase II Study of PS-341 [bortezomib] (LDP-341, NSC 681239) in Patients With Advanced or Metastatic Sarcoma

Trial Profile

A Multi-Institutional, Open-Label, Two-Group, Phase II Study of PS-341 [bortezomib] (LDP-341, NSC 681239) in Patients With Advanced or Metastatic Sarcoma

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Dec 2009

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Ewing's sarcoma; Gastrointestinal stromal tumours; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Dec 2009 Actual end date (May 2004) added as reported by ClinicalTrials.gov.
    • 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 May 2007 Status changed from suspended to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top